VAV2

Across TCGA pan-cancer cohorts, VAV2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VAV2 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VAV2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VAV2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where VAV2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.379	0.714	<.001	74	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.413	.018	16	view →
CCRCC	DFS	Tertile	II,III,IV	0.928	0.149	.020	15	view →
LSCC	DFS	Tertile	II,III,IV	0.836	1.000	.018	6	view →
HNSC	DFS	Quartile	IV	0.872	0.553	.033	4	view →
LUAD	OS	Quartile	II,III,IV	0.553	1.000	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VAV2–PDAC (OS)

Open the PDAC breakdown →